Literature DB >> 1488792

Schizophrenia--a high-risk factor for suicide: clues to risk reduction.

C B Caldwell1, I I Gottesman.   

Abstract

Suicide is the chief cause of premature death among schizophrenic persons. The lifetime incidence of suicide for patients with schizophrenia is 10% to 13% compared to a general population estimate of about 1%, and is quite close to that observed among those with major affective disorder. The magnitude of increased risk for suicide among schizophrenics peaks before middle age and declines thereafter, although schizophrenic persons tend to be at increased risk throughout the life span. Among psychiatric patients, schizophrenics are overrepresented among suicides, and often schizophrenics constitute the majority of inpatient suicides. It is important in evaluating suicide risk among schizophrenic persons to assess depression and suicidal ideation especially during index admission and during acute phases of the illness. It is noteworthy that schizophrenic persons often commit suicide as the overall level of psychopathology decreases during a nonpsychotic phase. Research has yielded salient risk factors for suicide in schizophrenic persons and "types" of especially vulnerable patients, even though statistical prediction of individual suicides has not proven effective.

Entities:  

Mesh:

Year:  1992        PMID: 1488792

Source DB:  PubMed          Journal:  Suicide Life Threat Behav        ISSN: 0363-0234


  27 in total

Review 1.  Drug treatments for schizophrenia.

Authors:  C Adams; P Wilson; S Gilbody; A M Bagnall; R Lewis
Journal:  Qual Health Care       Date:  2000-03

Review 2.  Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options.

Authors:  Herbert Y Meltzer
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

3.  Suicidal behavior in adolescents with first-episode psychosis.

Authors:  Tatiana Falcone; Leenu Mishra; Erin Carlton; Catherine Lee; Robert S Butler; Damir Janigro; Barry Simon; Kathleen Franco
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-04

Review 4.  Concise review: the promise of human induced pluripotent stem cell-based studies of schizophrenia.

Authors:  Kristen J Brennand; Fred H Gage
Journal:  Stem Cells       Date:  2011-12       Impact factor: 6.277

5.  Antecedents and patterns of suicide behavior in first-admission psychosis.

Authors:  Shelly Bakst; Jonathan Rabinowitz; Evelyn J Bromet
Journal:  Schizophr Bull       Date:  2009-03-09       Impact factor: 9.306

Review 6.  Chlorpromazine versus penfluridol for schizophrenia.

Authors:  Naemeh Nikvarz; Mostafa Vahedian; Navid Khalili
Journal:  Cochrane Database Syst Rev       Date:  2017-09-23

7.  Persistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension.

Authors:  Amresh Shrivastava; Megan E Johnston; Nilesh Shah; Marco Innamorati; Larry Stitt; Meghana Thakar; David Lester; Maurizio Pompili
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

8.  A cross-sectional study of co-occurring suicidal and psychotic symptoms in inpatients at mathari psychiatric hospital, nairobi, kenya.

Authors:  David M Ndetei; Matteo Pizzo; Lincoln I Khasakhala; Victoria N Mutiso; Francisca A Ongecha; Donald A Kokonya
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

9.  The interactive effects of negative symptoms and social role functioning on suicide ideation in individuals with schizophrenia.

Authors:  Danielle R Jahn; Melanie E Bennett; Stephanie G Park; Raquel E Gur; William P Horan; Ann M Kring; Jack J Blanchard
Journal:  Schizophr Res       Date:  2015-12-30       Impact factor: 4.939

Review 10.  Fluphenazine (oral) versus placebo for schizophrenia.

Authors:  Hosam E Matar; Muhammad Qutayba Almerie; Stephanie Sampson
Journal:  Cochrane Database Syst Rev       Date:  2013-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.